Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT05176470 2026-02-24

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Phase 1 Active not recruiting

2 enrolled

Dermatologic

Melanoma

NCT05603910 2026-02-24

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Phase 1 Recruiting

18 enrolled

Gynecologic

Endometrial Neoplasms

NCT06475235 2026-02-20

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Phase 1 Recruiting

15 enrolled

Lymphoid

Lymphoma

NCT07300475 2026-02-13

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Phase 1 Not yet recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Phase 1 Not yet recruiting

35 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03932409 2026-02-10

FIERCE

Phase 1 Active not recruiting

45 enrolled

Gynecologic

Endometrial Neoplasms

NCT05082259 2026-02-10

ASTEROID

Phase 1 Recruiting

61 enrolled

BreastGynecologic

Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms

NCT03237572 2026-02-09

Breast-48

Phase 1 Terminated

13 enrolled 10 charts

Breast

Breast Neoplasms

NCT04297605 2026-02-09

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Phase 1 Recruiting

28 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06378047 2026-02-09

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Phase 1 Completed

2 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04166734 2026-02-04

MESO-PRIME

Phase 1 Terminated

5 enrolled 13 charts

Other solid neoplasmThoracic

Mesothelioma

NCT07385846 2026-02-04

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

Phase 1 Not yet recruiting

8 enrolled

CNS

Turcot syndrome, Glioblastoma

NCT04754321 2026-02-02

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

Phase 1 Recruiting

45 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03295227 2026-01-30

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

Phase 1 Recruiting

37 enrolled

Thoracic

Thymoma

NCT02600949 2026-01-29

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

Phase 1 Active not recruiting

117 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02999477 2026-01-29

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

Phase 1 Completed

32 enrolled 23 charts

Breast

Breast Neoplasms

Clinical Trials

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

PEACH

Phase Ib of L-NMMA and Pembrolizumab

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

GRAIN

MATCHPOINT

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

FIERCE

ASTEROID

Breast-48

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

MESO-PRIME

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer